NEW YORK--(BUSINESS WIRE)--IRX Therapeutics, a privately-held company dedicated to the discovery and development of proprietary drugs for the treatment of cancer and viral diseases, today announced that findings from its Phase 2b clinical trial of IRX-2 will be presented at a symposium on May 8, 2008 at 15:45 during the 3rd European Conference on Head and Neck Oncology at the Westin Hotel in Zagreb, Croatia.
